Sutro Biopharma Inc. (STRO)’s Financial Results Comparing With Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP)

Sutro Biopharma Inc. (NASDAQ:STRO) and Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) compete against each other in the Biotechnology sector. We will compare them and contrast their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sutro Biopharma Inc. 23.37M 11.02 49.17M -2.21 0.00
Corbus Pharmaceuticals Holdings Inc. 2.89M 165.30 49.06M -0.87 0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Sutro Biopharma Inc. and Corbus Pharmaceuticals Holdings Inc.

Profitability

Table 2 shows us the return on assets, net margins and return on equity of both businesses.

Net Margins Return on Equity Return on Assets
Sutro Biopharma Inc. -210.40% 0% 0%
Corbus Pharmaceuticals Holdings Inc. -1,697.58% -88.5% -71.2%

Liquidity

3.5 and 3.5 are the respective Current Ratio and a Quick Ratio of Sutro Biopharma Inc. Its rival Corbus Pharmaceuticals Holdings Inc.’s Current and Quick Ratios are 3.5 and 3.5 respectively. has a better chance of clearing its pay short and long-term debts than .

Analyst Ratings

The table given features the ratings and recommendations for Sutro Biopharma Inc. and Corbus Pharmaceuticals Holdings Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Sutro Biopharma Inc. 0 0 0 0.00
Corbus Pharmaceuticals Holdings Inc. 0 0 4 3.00

On the other hand, Corbus Pharmaceuticals Holdings Inc.’s potential upside is 243.59% and its consensus target price is $26.25.

Insider & Institutional Ownership

The shares of both Sutro Biopharma Inc. and Corbus Pharmaceuticals Holdings Inc. are owned by institutional investors at 71.8% and 44.3% respectively. Insiders held 8.5% of Sutro Biopharma Inc. shares. Comparatively, insiders own roughly 3.7% of Corbus Pharmaceuticals Holdings Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Sutro Biopharma Inc. 14.01% -8% 0% 0% 0% -21.32%
Corbus Pharmaceuticals Holdings Inc. -2.03% -11.29% 25.19% 15.56% -9.87% -4.79%

For the past year Corbus Pharmaceuticals Holdings Inc. has weaker performance than Sutro Biopharma Inc.

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Corbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases. Its lead product candidate includes JBT-101, a novel oral endocannabinoid-mimetic drug, which is in Phase 2 clinical trials for the treatment of systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis, and systemic lupus erythematosus diseases. The company is based in Norwood, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.